Digital Dose Inhaler Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Digital Dose Inhaler Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The digital dose inhaler market is anticipated to grow with a CAGR of above 13.3% during the forecast period.

COVID-19 pandemic had a significant impact on the global digital dose inhaler market, due to patients with asthma and chronic obstructive pulmonary disease (COPD) being considered at increased risk of hospitalization from COVID-19. According to the article titled "Risk of serious COVID-19 outcomes among adults with asthma in Scotland: a national incident cohort study" published in January 2022 adults with asthma were found to be at an increased risk of COVID-19 hospital admission compared with those without asthma conditions. Thus, increasing cases of COVID-19 are rising the cases of respiratory disorders which generates the need for digital dose inhalers. Thus COVID-19 had a significant impact on the growth of the market during the pandemic period.

The major factors attributing to the growth of the digital dose inhaler market include the rising prevalence of chronic respiratory diseases and the growing demand for technology-enabled features of respiratory devices.

Soaring geriatric populations suffering from respiratory disorders and favorable reimbursement policies also play a significant role in the growth of the market. According to the article titled "Common Respiratory Disorders in Seniors" published in April 2020 around 15% of older adults from asthma, chronic obstructive pulmonary disease, or another respiratory disorder. The rising prevalence of respiratory diseases globally is expected to drive the demand for digital dose inhalers, thereby contributing to the growth of the market.

Additionally, the increasing product launches are expected to contribute to the growth of the market. For instance, in December 2021 NuvoAir, launched an add-on sensor for asthma and chronic obstructive pulmonary disease inhalers as a part of its chronic care ecosystem.

Thus, the above-mentioned factors are expected to drive the growth of the market over the forecast period. However, the high cost of the inhalers is a constraint to the growth of the market.

Key Market TrendsDry Powder Inhalers (DPI) are Expected to Hold a Major Share in the Growth of the Market Over the Forecast Period

Dry powder inhalers are devices that deliver medication to the lungs in the form of a dry powder. The major factors attributing to the growth of the dry powder inhaler segment are the prevalence of chronic respiratory diseases like COPD, Asthma, etc., and the growing demand for technology-enabled features of respiratory devices.

Problems related to the occurrences of drug irritation caused by the existence of propellant components, such as chlorofluorocarbons (CFCs) in MDI, have boosted the usage of the DPIs, with lesser irritant impacts while providing therapeutic efficacy as MDIs.Hence the DPIs are called green inhalers.

Additionally, the increasing product launches are also expected to contribute to the growth of the studied segment during the forecast period. For instance, in December 2020, Berry Global launched the RS01 single-dose dry powder inhaler with built-in sensors and digital capabilities. The RS01 tracks inhaler use and connects to a companion app that provides personalized guidance to improve adherence and inhaler technique.

Thus the above-mentioned factors are expected to drive the growth of the studied segment during the forecast period.

North America Dominates the Market and Expected to do Same Over the Forecast Period

North America is expected to dominate the overall digital dose inhaler market throughout the forecast period. The increase in the prevalence of respiratory conditions among both the pediatric and the elderly population will further benefit market growth.

In the United States, asthma is more common in adult women than in adult men. According to the Centers for Disease Control and Prevention (CDC) published in May 2022, 7.8% of the population in the United States had prevalent asthma in 2020. The report also mentioned that the prevalence of asthma in females was 9.5% and 6.1% in males in 2020.

Also, the increasing product launches are expected to drive the growth of the market in this region. For instance, in September 2020 Teva Pharmaceuticals launched the AirDuo Digihare and ArmonAir Digihaler inhalation powder, two digital maintenance inhalers for patients with asthma.

Thus the above-mentioned factors are expected to drive the growth of the market during the forecast period in this region.

Competitive Landscape

The digital dose inhaler market is moderately competitive and consists of key market players. Some of the companies which are currently dominating the market include Glenmark Pharmaceuticals Ltd., AstraZeneca Plc, Novartis International AG, Propeller Health, Philips Respironics, Opko Health, Inc., and Teva Pharmaceutical Industries Ltd.

Additional Benefits:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.


1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Chronic Respiratory Diseases
4.2.2 Soaring Geriatric Population Afflicted With Respiratory Disorders
4.2.3 Increasing R&D Investment for Technological Improvement and Device Miniaturization
4.3 Market Restraints
4.3.1 High Cost of the Devices
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 By Product
5.1.1 Dry Powder Inhalers
5.1.2 Metered Dose Inhalers
5.2 By Application
5.2.1 Chronic Obstructive Pulmonary Disease
5.2.2 Asthma
5.2.3 Others
5.3 By Type
5.3.1 Branded
5.3.2 Generic
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Glenmark Pharmaceuticals
6.1.2 Novartis International AG
6.1.3 Propeller Health
6.1.4 Koninklijke Philips N.V.
6.1.5 Opko Health, Inc.
6.1.6 Teva Pharmaceutical Industries Ltd.
6.1.7 H&T Presspart Manufacturing Ltd
6.1.8 AptarGroup Inc
6.1.9 Amiko Digital Health Limited
6.1.10 Pneuma Respiratory
6.1.11 Trudell Medical UK Limited
6.1.12 BreatheSuite Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings